Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Gross Profit data on file, last reported at $52.2 million in Q1 2026.

• Quarterly Gross Profit rose 47.1% year-over-year to $52.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222.3 million (up 101.91% YoY) and the FY2025 annual result came in at $205.6 million, up 118.28% from the prior year.
• Gross Profit eased to $52.2 million in Q1 2026 per ADPT's latest filing, from $53.5 million in the prior quarter.
• The five-year high for Gross Profit was $75.8 million in Q3 2025, with the low at -$16.2 million in Q2 2023.
• Average Gross Profit over 5 years is $30.3 million, with a median of $26.3 million recorded in 2022.
• Year-over-year, Gross Profit plunged 153.13% in 2023 and soared 241.45% in 2024.
• Adaptive Biotechnologies' Gross Profit stood at $31.5 million in 2022, then grew by 17.22% to $36.9 million in 2023, then dropped by 29.86% to $25.9 million in 2024, then surged by 106.53% to $53.5 million in 2025, then dropped by 2.42% to $52.2 million in 2026.
• Business Quant data shows ADPT's Gross Profit at $52.2 million in Q1 2026, $53.5 million in Q4 2025, and $75.8 million in Q3 2025.